Regarding oncogenic cellular signaling pathways and CHD, mTOR inhibitors were shown to decrease the expression of 5-HT receptors on valve cells, having to be preferred to other cardiotoxic treatments, such as sunitinib, in patients with NETs at risk of developing CHD. Here, MTOR is linked to coronary artery disorder.